unit
state
armi
medic
research
institut
infecti
diseas
list
four
rna
viral
famili
prime
etiolog
agent
viral
hemorrhag
fever
vhf
arenavirida
argentin
bolivian
brazilian
venezuelan
hemorrhag
fever
lassa
fever
bunyavirida
hantaviru
genu
congocrimean
hemorrhag
fever
cchf
nairoviru
genu
rift
valley
fever
viru
phleboviru
genu
filovirida
ebola
marburg
virus
flavivirida
dengu
yellow
fever
refer
list
import
characterist
classifi
arenavirida
virus
bunyavirida
virus
filovirida
virus
flavivirida
virus
respect
vhf
agent
pose
real
threat
terror
weapon
follow
reason
except
marburg
ebola
virus
wide
distribut
natur
mani
natur
spread
airborn
mean
human
wide
suscept
seriou
often
lifethreaten
infect
differenti
diagnosi
encompass
wide
varieti
organ
rickettsi
diseas
leptospirosi
relaps
fever
malaria
typhoid
shigellosi
sepsi
other
make
initi
recognit
vhf
viru
attack
difficult
distinguish
great
similar
clinic
present
vhf
make
nearli
imposs
differenti
without
sophist
timeconsum
laboratori
analysi
vhf
respond
antivir
therapi
need
treat
immedi
clinic
separ
viral
pathogen
lack
specif
therapi
limit
prophylact
therapeut
option
isol
identif
vhf
agent
frequent
requir
biosafeti
level
laboratori
lifesav
support
therapi
often
requir
intens
care
bed
impract
mass
casualti
situat
fortun
vhf
cchf
lassa
fever
and
virus
ebola
viru
marburg
viru
exhibit
secondari
humantohuman
spread
especi
nosocomi
set
articl
present
virolog
patholog
clinic
present
control
measur
avail
limit
number
vhf
agent
assist
practition
earli
recognit
therapeut
option
threat
arenavirida
arenavirus
spheric
pleomorph
envelop
singlestrand
biseg
rna
ambisens
virus
use
virion
rnadepend
rna
polymeras
replic
first
arenaviru
isol
lymphocyt
choriomening
viru
first
arenaviru
hemorrhag
fever
viru
isol
junin
viru
caus
argentin
hemorrhag
fever
machupo
viru
isol
case
bolivian
hemorrhag
fever
lassa
viru
isol
arenaviru
speci
least
seven
caus
hemorrhag
fever
lassa
fever
viruslassa
fever
junin
virusargentin
hemorrhag
fever
machupo
virusbolivian
hemorrhag
fever
guanarito
virusvenezuelan
hemorrhag
fever
sabia
virushemorrhag
fever
extens
hepat
necrosi
whitewat
arroyo
virushemorrhag
fever
liver
failur
olivero
virushemorrhag
fever
arenavirus
caus
chronic
asymptomat
infect
rodent
persist
rodent
infect
caus
molecular
mechan
failur
host
immun
system
congenit
neonat
infect
result
hightit
lifelong
viral
infect
abund
urinari
excret
plaqueform
unit
per
millilit
urin
acut
infect
cytopath
effect
rodent
cell
remain
infect
life
human
nonreservoir
host
inhal
aerosol
contain
viru
viru
shown
enter
gastrointestin
respiratori
epitheli
cell
apic
plasma
membran
cellular
receptor
old
world
arenavirus
lassa
fever
viru
lymphocyt
choriomening
viru
seem
adystroglycan
adystroglycan
cell
surfac
receptor
link
extracellular
matrix
actinbas
cytoskeleton
attach
local
viral
replic
viru
spread
hilar
lymph
node
lung
organ
pulmonari
consolid
interstiti
infiltr
edema
occur
initi
macrophag
infect
follow
widespread
epitheli
involv
fatal
case
fulmin
viremia
believ
caus
failur
delay
cellular
immun
respons
pathogen
lassa
viru
relat
resist
interferon
one
studi
howev
interferon
sensit
lassa
viru
isol
correl
lethal
pichind
viru
infect
human
use
guinea
pig
model
mimic
human
lassa
fever
day
infect
initi
viremia
weight
loss
fever
macrophag
cell
primarili
infect
epitheli
cell
becom
infect
littl
involv
endotheli
cell
focal
necrosi
liver
adren
gland
mild
interstiti
pneumon
margin
zone
necrosi
splenic
white
pulp
intestin
villou
blunt
seen
histolog
guinea
pig
develop
progress
decreas
cardiac
output
caus
carditi
releas
solubl
inflammatori
mediat
ie
tumor
necrosi
factora
balbc
neonat
mous
model
pichind
viral
infect
fatal
mice
surviv
mice
viru
gradual
clear
could
detect
month
kidney
brain
anim
high
antibodi
titer
major
histocompat
group
restrict
cytotox
tcell
activ
pichind
viru
experi
requir
biosafeti
level
laboratori
pirit
viru
coexist
region
venezuela
guanarito
viru
caus
venezuelan
hemorrhag
fever
origin
isol
cotton
rat
sigmodoni
alstoni
viru
provid
anoth
model
mimic
fatal
human
lassa
fever
infect
syrian
golden
hamster
mesocricetu
auratu
golden
hamster
develop
interstiti
pneumon
splenic
lymphoid
deplet
necrosi
multifoc
hepat
necrosi
without
great
deal
inflammatori
infiltr
special
stain
situ
termin
deoxynucleotidyl
transferasemedi
dutp
nickend
label
stain
demonstr
hepatocyt
undergo
apoptosi
necrapoptosi
model
requir
biosafeti
level
laboratori
south
american
hemorrhag
fever
patient
develop
bleed
secondari
sever
thrombocytopenia
caus
part
interferoninduc
matur
arrest
megakaryocyt
lassa
fever
like
caus
hepat
failur
thrombocytopenia
risk
death
lassa
fever
correl
high
aspart
transaminas
serum
level
bunyavirida
famili
anim
plant
virus
consist
speci
definit
tent
divid
five
genera
four
genera
infect
anim
one
infect
plant
viru
first
isol
aed
mosquito
yellow
fever
epidem
bunyavirida
spheric
envelop
virus
nm
diamet
genom
consist
larg
design
l
medium
small
singlestrand
negativesens
rna
complimentari
nucleotid
end
within
genu
termin
nucleotid
sequenc
conserv
differ
significantli
genu
genu
within
bunyavirida
famili
member
famili
contain
viral
sens
rna
wherea
phleboviru
tospoviru
genera
also
contain
complimentari
sens
rna
bunyaviru
hantaviru
nairoviru
genera
use
negativesens
code
wherea
phleboviru
includ
rift
valley
fever
tospoviru
plant
diseas
genera
use
ambisens
code
bunyaviru
patholog
exemplifi
california
enceph
la
cross
jamestown
canyon
virus
cycl
begin
asymptomat
amplifi
infect
natur
vertebr
host
adult
chipmunk
squirrel
fox
woodchuck
la
cross
viru
whitetail
deer
jamestown
viru
snowsho
hare
snowsho
hare
viru
mosquito
ie
aed
triseriatu
la
cross
viru
culiseta
inorata
jamestown
viru
becom
infect
feed
anim
viru
replic
mosquito
midgut
dissemin
organ
includ
ovari
mosquito
salivari
gland
mosquito
bite
turn
infect
human
mosquito
ovarian
infect
import
maintain
viru
mosquito
popul
human
viru
spread
subcutan
tissu
skelet
muscl
replic
secondarili
spread
lymphat
distant
skelet
cardiac
muscl
anoth
round
replic
take
place
viru
dissemin
central
nervou
system
replic
neuron
glial
cell
follow
neuron
cell
necrosi
death
occur
day
brain
lesion
princip
cerebr
cortex
brainstem
consist
edema
perivascular
cuf
glial
nodul
leptomening
area
focal
necrosi
doerr
demonstr
phlebotomu
fever
caus
filter
agent
phleboviru
caus
rift
valley
fever
first
isol
newborn
lamb
epidem
sheep
caus
abort
high
mortal
sandfli
fever
sicilian
napl
virus
isol
american
troop
palermo
napl
similar
diseas
describ
napoleon
war
abort
storm
describ
earli
rift
valley
fever
swept
herd
cattl
sheep
recent
abort
storm
attribut
equin
herpesviru
type
especi
armi
ffetal
strain
coxiella
burnetii
thogoto
viru
transmit
ixodid
tick
neospora
caninum
one
strain
equin
arter
viru
import
awar
abort
storm
may
earli
sign
zootic
bioterrorist
attack
hemorrhag
fever
viru
agent
unfortun
abort
storm
etiolog
agent
ever
identifi
rift
valley
fever
infect
initi
bite
infect
mosquito
inocul
viru
trap
local
lymph
node
replic
becom
sourc
primari
viremia
major
organ
infect
second
round
replic
take
place
distant
lymph
node
spleen
liver
adren
lung
kidney
necrot
foci
develop
liver
brain
patient
clinic
enceph
hemorrhag
fever
thrombocytopenia
fibrin
deposit
major
organ
seen
punta
toro
viru
infect
hamster
becom
experiment
model
rift
valley
fever
model
liver
injuri
respons
hemorrhag
complic
viral
replic
directli
caus
apoptosi
cellular
viabil
decreas
hour
infect
caspas
activ
phosphatidylserin
transloc
dna
fragment
occur
hour
viral
infect
alon
without
system
inflammatori
reaction
induc
hemorrhag
diseas
suggest
target
therapeut
nairoviru
genu
consist
tickborn
virus
transmit
culicoid
fli
mosquito
cchf
tick
speci
hyalomma
dermacentor
rhipicephalu
fli
nairobi
sheep
diseas
tick
fli
mosquito
cchf
worldwid
distribut
mirror
hyalomma
tick
close
speci
diseas
report
throughout
subsaharan
africa
south
africa
madagascar
middl
east
european
russia
pakistan
afghanistan
central
asian
republ
bulgaria
former
yugoslavia
northern
greec
xijiang
provinc
northern
china
cchf
nairovirus
surviv
variou
tick
lifestag
transstadi
transmiss
tick
gener
gener
transovarian
transmiss
vertebr
includ
groundfeed
bird
european
russia
bulgaria
greec
provid
bloodmeal
infect
tick
becom
infect
viral
sourc
uninfect
tick
viral
amplif
sheep
goat
cattl
ostrich
larg
wild
herbivor
hare
hedgehog
known
amplifi
cchf
sheep
goat
known
amplifi
nairovirus
africa
distribut
nairoviru
infect
follow
distribut
tick
host
rhipicephalu
appendiculatu
middl
east
india
distribut
human
infect
follow
haemaphysali
intermedia
tick
close
relat
ganjam
viru
nairoviru
reproduc
spleen
liver
kidney
sheep
goat
suckl
mous
infect
vascular
endothelium
becom
primari
viral
target
edema
necrosi
capillari
wall
mucosa
intestin
gallbladd
femal
genit
tract
seen
develop
hemorrhag
inflamm
human
local
viral
replic
follow
spread
blood
lymphat
major
organ
especi
liver
edema
hemorrhag
necrosi
diffus
intravascular
coagul
dic
thrombocytopenia
expect
abnorm
coagul
profil
igm
igg
respons
detect
day
survivor
absent
fatal
case
hantaviru
genu
first
came
medic
attent
public
case
hemorrhag
fever
renal
syndrom
case
acut
febril
ill
hemorrhag
manifest
report
among
unit
nation
troop
korean
war
first
known
korean
hemorrhag
fever
commonli
refer
hemorrhag
fever
renal
syndrom
hfr
apodemu
agrariu
field
mous
found
reservoir
viru
first
isol
design
hantaan
viru
hantaan
river
korea
mani
origin
case
describ
rattu
norvegicu
r
rattu
host
seoul
viru
caus
urban
hfr
scandinavia
nephropathia
epidemica
renal
diseas
mild
without
hemorrhag
manifest
caus
puumala
viru
spread
clethrionomi
glareolu
bank
vole
insectivor
harbor
hantaviru
suncu
murinu
indian
tree
shrew
prospect
hill
viru
first
hantaviru
caus
human
diseas
describ
america
microtu
pennsylvanicu
meadow
vole
host
sever
hfr
balkan
caus
dobrava
viru
associ
apodemu
flavicolli
least
three
subfamili
speci
hantavirus
caus
either
hfr
hantaviru
pulmonari
syndrom
hp
southwestern
unit
state
four
corner
region
meet
point
new
mexico
arizona
colorado
utah
outbreak
influenzatyp
ill
rapidli
progress
respiratori
failur
shock
death
day
hp
found
caus
hantaviru
sin
nombr
reservoir
deer
mous
peromyscu
maniculatu
argentina
akodon
azara
abund
rodent
hantaviru
seropreval
first
outbreak
hp
central
america
lo
santo
panama
occur
case
nine
confirm
serolog
three
fatal
household
neighborhood
serolog
studi
found
seroposit
suggest
persontoperson
spread
western
venezuela
home
mapor
viru
close
relat
south
american
hp
virus
infect
fulvou
pygmi
rice
rat
oligoryzomi
fulvescen
sinc
discoveri
differ
hantavirus
differ
rodent
reservoir
shown
caus
hp
throughout
north
south
america
identif
highrisk
area
essenti
control
human
infect
bayou
viru
second
lead
caus
hp
unit
state
rodent
host
includ
oryzomi
palustri
commonli
infect
speci
seropreval
rate
sigmodon
hispidu
peromyscu
leucopu
reithrodontomi
fulvescen
baiomi
taylori
heaviest
male
rodent
highest
seropreval
seropreval
higher
coastal
prairi
oldfield
directli
relat
host
popul
densiti
first
case
hp
maranhao
state
brazil
identifi
virus
design
anajatuba
rio
mamor
virus
isol
oligoryzomi
fornesi
gikicguki
scuyrey
two
case
hp
appear
two
area
central
bolivia
dens
forest
destroy
replac
pastur
sugarcan
oligoryzomi
microti
calomi
callosu
identifi
rodent
reservoir
associ
human
diseas
interest
note
neither
hp
hfr
report
australia
despit
fact
hantaviru
antibodyposit
rodent
found
across
contin
hantaviru
establish
asymptomat
infect
natur
rodent
reservoir
persist
month
year
atrisk
area
diseas
spread
horizont
scratch
bite
infect
aerosol
among
rodent
viru
spread
organ
particularli
concentr
kidney
lung
high
rate
replic
salivari
gland
viru
shed
urin
fece
saliva
peak
week
infect
continu
life
although
reduc
quantiti
rise
antibodi
titer
cell
death
observ
infect
animalhost
seropreval
studi
endem
area
found
r
norvegicu
frequent
infect
speci
kinmen
studi
r
norvegicu
mu
musculu
r
flavipectu
hantaviru
infect
asymptomat
go
undetect
india
report
either
hp
hrf
studi
patient
febril
ill
found
seroposit
enzym
immunoassay
igm
direct
hantaviru
eighteen
patient
posit
indirect
immunofluoresc
assay
studi
healthi
blood
donor
posit
enzym
immunoassay
patient
posit
immunofluoresc
assay
similar
survey
kinmen
island
china
taiwan
found
seropreval
among
scrub
typhusneg
individu
hp
hfr
infect
human
inhal
infect
rodent
excreta
cytopatholog
effect
infect
human
cell
lethal
patholog
seem
immun
modul
direct
result
viral
induct
cell
apoptosi
bunyavirida
infect
akaban
aino
virus
caus
abort
stillbirth
congenit
defect
cattl
sheep
goat
also
result
induct
apoptosi
paradox
serolog
test
individu
frequent
occup
contact
rodent
littl
evid
exposur
sin
nombr
viru
caus
hp
whitewat
arroyo
viru
arenavirida
ampari
viru
hfr
patient
acut
tubulointerstiti
nephriti
puumala
virusassoci
hfr
result
interstiti
infiltr
lymphocyt
plasma
cell
monocytemacrophag
neutrophil
eosinophil
granulocyt
hp
hfr
gener
increas
product
cytokin
monocyt
macrophag
play
import
role
hp
hfr
pathophysiolog
viral
infect
caus
hfrsinfect
cell
undergo
complex
metabol
chang
result
infect
cell
increas
bactericid
activ
staphylococcu
aureu
ebola
marburg
make
two
genera
filovirida
genera
envelop
singlestrand
negativesens
rna
virus
ebola
bacilliform
bentpin
shape
marburg
filament
shape
ebola
viru
first
isol
identifi
genet
sequenc
publish
marburg
viru
first
describ
gene
sequenc
publish
four
speci
ebola
viru
zair
sudan
reston
cote
divoir
one
speci
marburg
viru
macaqu
develop
diseas
similar
human
inhal
inject
viru
zair
speci
virul
case
fatal
rate
reston
speci
least
virul
viral
infect
produc
viral
cytopatholog
cytokinemedi
vascular
leak
impair
host
respons
macrophag
monocyt
earliest
cell
infect
damag
host
immun
respons
facilit
spread
viru
patient
die
either
ebola
marburg
hemorrhag
fever
exhibit
necrosi
parenchym
cell
liver
spleen
kidney
ovari
test
liver
hepatocellular
necrosi
intact
hyalin
ghostlik
cell
amid
cellular
debri
fill
virion
intact
hepatocyt
display
intracytoplasm
inclus
bodi
repres
aggreg
viral
nucleocapsid
injuri
microvasculatur
kupffer
cell
capillari
endothelium
increas
endotheli
permeabl
contribut
shock
bleed
lymphoid
deplet
spleen
lymph
node
vascular
follicular
necrosi
fatal
case
antibodi
respons
survivor
patient
protract
cours
patient
develop
delay
humor
respons
peter
cowork
provid
detail
summari
patholog
effect
filovirus
virus
suppress
induct
interferon
protein
block
interferon
action
protein
transmiss
diseas
persontoperson
aerosol
spread
nonhuman
primat
document
believ
droplet
spread
common
persontoperson
vehicl
among
infect
human
aerosol
spread
probabl
rare
handl
infect
monkey
implic
case
sourc
natur
remain
unknown
although
recent
evid
asymptomat
infect
fruit
bat
report
cuba
walter
reed
jame
carrol
us
armi
medic
corp
prove
dr
carlo
finlay
theori
yellow
fever
transmit
mosquito
yellow
fever
viru
first
flaviviru
isol
grown
vitro
speci
flavivirus
flavivirida
spheric
envelop
singlestrand
positivesens
rna
virus
flavivirida
consist
three
genera
natur
transmiss
flavivirus
may
take
place
transfer
viru
host
host
contamin
mouthpart
mosquito
like
either
arthropod
mosquito
acquir
viru
blood
meal
viru
replic
epitheli
cell
line
mesenteron
midgut
replic
viru
escap
hemocel
infect
salivari
gland
secret
saliva
next
feed
infect
new
host
dengu
virus
viru
may
enter
number
mosquito
ova
directli
infect
mosquito
progeni
dengu
viru
surviv
two
host
vector
reservoir
aegypti
aed
speci
common
mosquito
vector
aegypti
requir
ml
viral
titer
human
becom
infect
blood
meal
help
select
strain
viru
rapidli
reproduc
nonhuman
primat
viru
replic
princip
monocyt
skin
lymph
node
spleen
liver
lung
thymu
dengu
fever
selflimit
skin
lesion
show
swell
endotheli
cell
small
vessel
perivascular
edema
monocyt
infiltr
dengu
hemorrhag
fever
result
sequenti
infect
primari
pathophysiolog
chang
dengu
hemorrhag
fever
vascular
permeabl
leakag
plasma
extravascular
compart
hemoconcentr
hypotens
believ
immun
reaction
second
infect
dengu
viru
result
dengu
hemorrhag
fever
preexist
antibodi
dengu
viru
heterolog
neutral
viru
permit
viru
replic
freeli
macrophag
second
theori
contend
viru
mutat
chimer
dengu
tickborn
enceph
west
nile
viru
liveattenu
vaccin
develop
control
method
consider
introduct
steril
male
mosquito
facilit
displac
insect
habitat
yellow
fever
viru
transmit
human
infect
human
infect
primat
treehol
breed
mosquito
haemagogu
janthinomi
haemagogu
sp
saabeth
chloropteru
aed
sp
usual
tropic
wet
season
earli
dri
season
hemorrhag
fever
virus
mosquito
introduc
viru
skin
replic
local
spread
region
lymph
node
viru
dissemin
bloodstream
liver
spleen
bone
marrow
myocardium
hallmark
diseas
steatosi
apoptosi
necrosi
mainli
midzon
region
liver
kupffer
cell
infect
follow
hepatocyt
midzon
liver
midzon
necrosi
develop
appear
councilman
bodi
indic
hepatocyt
apoptosi
minimum
mononuclear
infiltr
predomin
apoptosi
necrosi
contribut
varieti
activ
lymphocyt
variou
cytokin
notabl
transform
growth
factorb
yellow
fever
vaccin
liveattenu
vaccin
given
everi
year
risk
produc
immun
recipi
experiment
compound
inhibit
yellow
fever
viru
dengu
viru
bovin
viral
diarrhea
viru
banzi
viru
west
nile
viru
may
becom
candid
chemotherapeut
agent
tickborn
flaviviru
hemorrhag
fever
kyasanur
forest
diseas
india
human
viru
produc
parenchym
degener
liver
kidney
hemorrhag
pneumonia
increas
reticuloendotheli
tissu
liver
spleen
mark
erythrophagocytosi
macaqu
develop
fatal
infect
lymph
tissu
necrosi
primat
develop
enceph
chromatolysi
neuron
focal
demyelin
primari
vector
haemaphysali
spinigera
tick
although
speci
ixodid
tick
also
implic
tick
transmit
viru
among
transstadi
transovari
transmiss
bat
grounddwel
bird
may
reservoir
cow
goat
sheep
also
becom
infect
epidemiolog
import
unknown
omsk
hemorrhag
fever
siberia
dermacentor
reticul
ixod
apronophoru
suspect
vector
arvicola
terrestri
believ
host
manag
vhf
involv
basic
diagnost
therapeut
prophylact
infect
control
concept
practic
monitor
system
contact
guidelin
must
understand
practic
make
clear
recommend
concern
controversi
treatment
recommend
guidelin
includ
follow
possibl
vhf
bioterror
incid
identifi
patient
develop
complet
differenti
diagnosi
often
includ
malaria
typhoid
gastroenter
meningococcemia
diseas
exampl
case
definit
may
found
page
refer
notifi
public
health
author
unit
state
territori
done
local
state
health
depart
clinic
laboratori
must
organ
prepar
qualiti
assur
activ
properli
handl
test
forward
indic
suspect
specimen
confirm
elimin
diagnosi
either
viral
isol
identif
viral
antigen
elisa
polymeras
chain
reaction
pcr
use
modern
antibodi
test
viral
isol
specimen
sent
biosafeti
level
laboratori
isol
patient
institut
strictli
enforc
infect
control
measur
strict
isol
neg
pressur
room
intens
care
like
requir
adequ
number
isol
bed
intens
level
care
may
deliv
preplan
detail
specif
protect
measur
recommend
prevent
nosocomi
spread
vhf
virus
includ
use
mask
power
airpurifi
respir
may
found
refer
page
special
train
necessari
laboratori
worker
handl
patient
specimen
postmortem
practic
environment
decontamin
linen
bed
hospit
room
forth
identifi
atrisk
contact
institut
prophylaxi
avail
recommend
public
health
author
present
time
ribavirin
prophylaxi
controversi
ongo
monitor
must
institut
atrisk
contact
selfmonitor
system
prefer
less
laborand
resourceintens
aggress
manag
patient
support
therapi
provid
specif
antivir
therapi
avail
begin
ribavirin
pend
identif
etiolog
agent
continu
treatment
arenaviru
bunyaviru
identifi
discontinu
therapi
flaviviru
filoviru
virus
respond
ribavirin
identifi
licens
vaccin
except
yellow
fever
ribavirin
prophylaxi
controversi
may
delay
onset
diseas
lassa
viru
lassa
fever
lassa
fever
viru
arenavirida
discov
year
ago
endem
west
equatori
africa
serosurvey
reveal
antibodi
preval
sierra
leon
guinea
nigeria
sierra
leon
guinea
nigeria
unit
nation
develop
program
estim
million
seroneg
atrisk
individu
million
firsttim
infect
per
year
million
reinfect
per
year
death
per
year
matomi
natalensi
rodent
principl
host
savannah
forest
region
antibodi
posit
mu
musculu
principl
host
coastal
urban
area
antibodi
posit
natalensi
caught
near
home
seroposit
five
percent
suscept
individu
seroconvert
year
ratio
ill
infect
seroconvert
febril
mortal
rate
estim
infect
peak
incid
believ
dri
season
januarymarch
sierra
leon
overlap
raini
season
maynovemb
incid
diseas
tropic
endem
region
may
drop
raini
season
difficulti
travel
viru
caus
death
among
peopl
per
year
infect
infect
mild
asymptomat
overal
mortal
mortal
patient
requir
hospit
lassa
fever
may
present
anywher
world
access
air
travel
guidelin
need
clear
practic
intern
aspect
need
consid
includ
need
reliabl
risk
assess
perform
patient
medic
evacu
selfmonitor
consid
activ
surveil
resourc
intens
although
incub
period
day
week
case
present
within
day
exposur
onset
diseas
gradual
fever
malais
myalgia
patient
develop
conjunctiv
inject
pharyng
white
yellow
exud
ulcer
cough
chest
pain
abdomin
pain
nausea
vomit
patient
mild
diseas
improv
within
day
sever
ill
patient
develop
facial
laryng
edema
cyanosi
mild
bleed
shock
patient
sever
diseas
commonli
complic
pleural
pericardi
effus
patient
note
mild
thrombocytopenia
dysfunct
platelet
patient
white
blood
cell
count
normal
reduc
commonli
lassa
fever
mild
elev
aspart
transaminas
level
patient
hepat
sever
thirti
percent
patient
develop
perman
late
sensorineur
deaf
sudden
onset
deaf
associ
lassa
viru
seroposit
relationship
sever
ill
initi
hear
loss
eventu
recoveri
patient
neurolog
complic
tremor
confus
seizur
coma
often
die
pregnant
women
highest
mortal
rate
lassa
viru
cross
placenta
commonli
result
abort
particularli
third
trimest
overal
mortal
hospit
patient
mortal
poor
prognost
sign
includ
pharyng
tachypnea
bloodi
diarrhea
high
fever
children
fever
cough
vomit
highest
overal
preval
among
age
group
girl
develop
clinic
diseas
differenti
diagnosi
lassa
hemorrhag
fever
includ
malaria
typhoid
vhf
meningococcemia
sepsi
sierra
leon
fever
pharyng
exud
ulcer
chest
pain
proteinuria
like
lassa
fever
case
admiss
patient
antibodi
viru
igg
igm
posit
elisa
lassa
viru
antigen
combin
igm
antibodi
sensit
specif
diagnosi
acut
lassa
fever
lassa
fever
acquir
rodent
excreta
either
inhal
contamin
food
persontoperson
transmiss
essenti
precaut
taken
recov
diseas
viremia
present
second
week
clinic
ill
viru
found
urin
week
semen
month
data
rel
risk
sexual
transmiss
diagnosi
made
isol
viru
blood
throat
swab
urin
biosafeti
level
laboratori
elisa
detect
lassa
viru
antigen
may
confirm
revers
transcriptas
rt
pcr
day
ill
specif
antibodi
test
igm
elisa
also
avail
replac
indirect
fluoresc
antibodi
test
laboratori
abnorm
includ
lymphocytopenia
thrombocytopenia
peak
day
prophylaxi
treatment
lassa
fever
includ
pregnant
women
highdos
intraven
ribavirin
recommend
g
intraven
load
dose
follow
g
intraven
everi
hour
day
follow
g
intraven
everi
hour
day
recommend
women
stop
breastfeed
anoth
recommend
intraven
regimen
initi
dose
mgkg
follow
mgkg
everi
hour
day
follow
mgkg
everi
hour
day
oral
ribavirin
dose
g
load
dose
follow
gd
four
divid
dose
day
follow
gd
six
dose
oral
ribavirin
believ
half
effect
intraven
therapi
intraven
ribavirin
given
within
day
begin
symptom
reduc
mortal
postexposur
prophylaxi
ribavirin
recommend
author
consist
g
oral
four
divid
dose
day
zidampidin
deriv
zidovudin
new
agent
seem
effect
treat
mous
model
lassa
vhf
control
rodent
near
dwell
strict
isol
hospit
patient
import
one
survey
ekpom
nigeria
captur
natalensi
rodent
posit
complement
fix
antibodi
lassa
viru
new
vaccin
includ
dna
minigen
vaccin
encod
lassa
viru
protein
fulllength
lassa
nucleoprotein
found
induc
tcell
respons
mice
protect
lymphocyt
choriomening
viru
pichind
viru
dna
vaccin
encod
nine
amino
acid
sequenc
lassa
nucleoprotein
also
induc
cell
protect
mous
model
viral
challeng
anoth
candid
vaccin
produc
attenu
recombin
vesicular
stomat
viru
express
lassa
viral
glycoprotein
vaccin
protect
nonhuman
primat
lethal
viral
challeng
none
test
anim
found
shed
viru
protect
humor
cellular
respons
occur
despit
document
lassa
fever
viru
viremia
day
challeng
none
vaccin
anim
display
evid
clinic
diseas
live
attenu
vaccin
produc
reassort
genom
segment
lassa
viru
mopeia
viru
encod
major
viral
antigen
nucleocapsid
glycoprotein
lassa
viru
rna
polymeras
zincbind
protein
mopeia
viru
immun
lassa
viru
demonstr
guinea
pig
mice
rhesu
macaqu
two
monkey
examin
reveal
histolog
lesion
sign
diseas
nonpathogen
uukuniemi
viru
bunyavirida
use
model
year
studi
molecular
cell
biolog
highli
pathogen
member
famili
approxim
case
lassa
fever
import
western
countri
result
secondari
clinic
case
contact
import
case
ivori
coast
way
lisbon
germani
studi
patient
diagnos
pcr
die
hemorrhag
fever
day
contact
close
contact
test
serolog
clinic
ill
report
physician
examin
patient
day
igg
antibodi
posit
ribavirin
mgkg
oral
four
time
daili
day
prophylaxi
start
highrisk
close
contact
index
case
diagnosi
confirm
eleven
patient
revers
increas
bilirubin
one
person
jaundic
day
therapi
nine
decreas
hemoglobin
recommend
manag
lassa
fever
europ
includ
follow
manag
patient
vari
neg
pressur
room
univers
precaut
netherland
complet
enclos
plastic
bubbl
unit
trexler
unit
unit
kingdom
staff
isol
suit
germani
use
trexler
unit
made
imposs
provid
intens
care
sickest
patient
isol
suit
made
difficult
staff
care
patient
hour
time
one
public
conclud
patient
hospit
mildli
ill
patient
may
manag
neg
pressur
room
strict
isol
patient
sever
ill
manag
highsecur
isol
facil
lowrisk
contact
monitor
consist
selfmonitor
temperatur
without
report
regularli
health
author
person
directli
contact
patient
bodi
fluid
blood
secret
selfmonitor
temperatur
report
regularli
health
depart
evid
efficaci
ribavirin
prophylaxi
limit
ideal
dose
g
mouth
per
day
two
divid
dose
germani
unit
kingdom
prophylaxi
offer
highrisk
contact
recommend
contact
inform
advers
reaction
offer
medic
viru
venezuelan
hemorrhag
fever
first
describ
natur
host
cane
mous
zygodontomi
brevicaudia
clinic
present
similar
argentin
hemorrhag
fever
fever
thrombocytopenia
bleed
patient
neurolog
complic
incub
mortal
treatment
prophylaxi
lassa
fever
convalesc
serum
therapi
may
also
effect
diagnosi
made
isol
viru
biosafeti
level
laboratori
realtim
pcr
assay
develop
sabia
viru
hemorrhag
fever
character
mark
liver
necrosi
may
mistaken
yellow
fever
case
success
treat
ribavirin
treatment
prophylaxi
lassa
fever
rodent
control
near
dwell
import
diagnosi
made
isol
viru
biosafeti
level
laboratori
realtim
pcr
assay
develop
lassa
fever
patient
argentin
hemorrhag
fever
present
nonspecif
ill
day
becom
extrem
ill
hypotens
petechia
soft
palat
axilla
gingiva
neurolog
find
common
lassa
fever
begin
fourth
day
ill
onset
hemorrhag
patient
irrit
letharg
display
muscular
hypotonia
hyporeflexia
areflexia
propriocept
disturb
inabl
ambul
tremor
tongu
hand
fluctuat
level
conscious
sever
ill
patient
bleed
mucou
membran
develop
shock
anuria
seizur
coma
untreat
die
diagnosi
made
first
day
ill
isol
viru
blood
throat
swab
urin
biosafeti
level
laboratori
junin
viru
antigen
igm
igg
antibodi
may
detect
elisa
test
realtim
pcr
assay
develop
treatment
prophylaxi
lassa
fever
convalesc
serum
therapi
may
also
effect
cation
peptid
cecropin
melittin
indolicidin
newer
agent
seem
activ
junin
viru
herp
simplex
ii
indolicidin
inactiv
cellfre
junin
viru
cecropin
activ
arenavirus
tacarib
pichind
rodent
control
near
dwell
import
liveattenu
vaccin
avail
increas
human
safeti
data
anim
efficaci
data
insuffici
human
efficaci
safeti
data
support
food
drug
administr
licensur
unfortun
vaccin
avail
argentina
candid
vaccin
manufactur
argentina
unit
state
studi
found
vaccin
manufactur
unit
state
safe
efficaci
argentinean
vaccin
found
equal
safe
immunogen
protect
guinea
pig
vaccin
manufactur
unit
state
oil
aromat
plant
nativ
san
lui
provinc
argentina
exhibit
antivir
activ
lippia
junelliana
l
turbinata
potent
bolivian
hemorrhag
fever
natur
endem
beni
region
northeast
bolivia
natur
host
rodent
c
callosu
incub
period
day
mortal
treatment
prophylaxi
lassa
fever
convalesc
serum
therapi
may
also
effect
diagnosi
made
isol
viru
biosafeti
level
laboratori
realtim
pcr
assay
develop
rodent
control
near
dwell
import
evid
crossprotect
junin
viru
vaccin
viru
whitewat
arroyo
viru
hemorrhag
fever
first
isol
whitethro
wood
rat
neotoma
albigula
northwestern
new
mexico
infect
mice
result
lymphocyt
mening
perivascular
lymphocyt
cuf
neonat
infect
mous
result
chronic
lifelong
infect
viral
shed
hand
case
rna
virus
replic
high
error
rate
potenti
rapidli
develop
drugresist
mutant
rather
chase
resist
strain
newer
antiinfect
agent
grandeperez
cowork
other
attempt
increas
replic
error
rate
forc
viral
extinct
resist
mutant
aris
vitro
cell
cultur
lymphocyt
choriomening
viru
treat
fluorouracil
phenomenon
seen
high
low
dose
mutagen
california
enceph
la
cross
viru
jamestown
canyon
viru
oropouch
viru
enceph
gener
febril
ill
usual
without
hemorrhag
fever
bunyamwera
viru
previous
refer
garissa
viru
isol
two
patient
serolog
detect
patient
larg
outbreak
hemorrhag
fever
kenya
tanzania
somalia
studi
two
isol
found
genet
reassort
alter
potenti
diseas
ngari
viru
respons
outbreak
garissa
viru
isol
ngari
viru
bunyamwera
viru
reassort
speci
rift
valley
fever
viru
zoonosi
commonli
caus
abort
livestock
herd
mortal
rumin
human
outbreak
associ
heavi
rainfal
sustain
flood
appear
larg
number
mosquito
human
becom
infect
mosquito
bite
handl
infect
anim
blood
tissu
although
humantohuman
transmiss
report
appropri
infect
control
procedur
use
incub
period
patient
develop
selflimit
nonspecif
febril
ill
patient
present
sudden
onset
fever
headach
joint
muscl
pain
conjunct
photophobia
patient
brief
initi
ill
partial
recoveri
symptom
return
follow
protract
convalesc
five
percent
patient
develop
retin
diseas
week
febril
ill
patient
experi
macular
exud
retin
hemorrhag
vascul
half
patient
perman
visual
impair
one
percent
develop
central
nervou
system
complic
one
percent
develop
typic
vhf
aggress
support
care
ribavirin
similar
dose
lassa
fever
recommend
therapi
complic
case
human
immun
serum
also
recommend
avail
viru
may
isol
blood
first
week
ill
intracerebr
inject
babi
mice
laboratoryacquir
case
report
viral
isol
perform
biosafeti
level
laboratori
rtpcr
detect
viru
blood
enzym
immunoassay
detect
igg
igm
treatment
prophylaxi
lassa
fever
live
attenu
vaccin
avail
livestock
formalinkil
rift
valley
fever
vaccin
avail
human
requir
annual
booster
mosquito
rodent
control
insect
repel
person
protect
cloth
essenti
prevent
ill
attenu
mutagenis
rift
valley
fever
viru
vaccin
rfv
mp
test
sheep
cattl
rhesu
macaqu
south
african
vaccin
strain
lumpi
skin
diseas
viru
type
saneethl
test
recombin
vaccin
express
structur
glycoprotein
gene
bovin
ephemer
fever
viru
two
glycoprotein
gene
rift
valley
fever
dna
vaccin
rift
valley
fever
cchf
tickborn
enceph
hantaan
viru
test
mice
rift
valley
fever
tickborn
enceph
vaccin
protect
wherea
two
vaccin
less
immunogen
first
case
recogn
modern
time
document
viru
isol
patient
crimean
diseas
found
ident
viru
isol
child
congo
human
infect
hyalomma
sp
tickbit
crush
infect
tick
skin
contact
blood
infect
livestock
infect
patient
blood
bodi
fluid
area
diseas
exhibit
biannual
peak
marchmay
augustoctob
incub
follow
tick
bite
day
incub
follow
contact
contamin
blood
day
nosocomi
transmiss
well
document
infect
symptomat
patient
present
sudden
onset
fever
chill
headach
dizzi
neck
pain
myalgia
lymphadenopathi
tender
hepatomegali
seen
patient
nausea
vomit
neuropsychiatr
symptom
cardiovascular
sign
symptom
manifest
patient
diseas
progress
patient
develop
nausea
vomit
diarrhea
patient
later
develop
flush
hemorrhag
especi
profus
gastrointestin
bleed
sever
ill
patient
develop
dic
renal
hepat
respiratori
failur
overal
mortal
laboratori
studi
reveal
leucopenia
thrombocytopenia
elev
transaminas
level
mortal
rang
treatment
consist
support
therapi
ribavirin
use
regimen
outlin
lassa
fever
world
health
organ
oral
regimen
mgkg
load
dose
follow
mgkg
everi
hour
day
follow
mgkg
everi
hour
day
therapi
approv
food
drug
administr
although
cchf
transmiss
aerosol
technic
difficulti
stand
way
mass
product
control
diseas
depend
tick
control
spray
camp
site
cloth
tickinfest
area
acaricid
repel
ribavirin
prophylaxi
effect
disinfect
decontamin
patient
must
care
strict
isol
written
procedur
establish
isol
unit
barrier
nurs
safeti
measur
handl
patient
specimen
laboratori
protocol
must
establish
enforc
earli
recognit
diseas
essenti
limit
spread
prevent
mortal
hemorrhag
fever
renal
syndrom
korean
war
unit
nation
troop
develop
symptom
complex
fever
hemorrhag
acut
renal
failur
shock
mortal
etiolog
agent
hantaan
viru
isol
field
mous
agrariu
relat
virus
dobrava
viru
balkan
caus
sever
hemorrhag
fever
seoul
viru
far
east
caus
milder
hemorrhag
fever
puumala
viru
scandinavia
caus
nephropathia
epidemica
puumala
viru
also
implic
case
hfr
usual
incub
period
week
may
rang
day
month
distinct
clinic
diseas
phase
describ
febril
phase
patient
present
acut
flulik
ill
low
back
pain
retroperiton
edema
flush
face
conjunctiv
pharyng
inject
secondari
vascular
dilat
hypotens
phase
second
phase
consist
mild
hypotens
shock
hemorrhag
lase
day
patient
may
manifest
petechia
develop
massiv
gastrointestin
bleed
lowgrad
dic
oligur
phase
third
phase
associ
hypertens
renal
failur
patient
pulmonari
edema
chang
mental
statu
untreat
death
occur
time
diuret
phase
diuret
phase
may
last
sever
month
laboratori
find
includ
thrombocytopenia
leukocytosi
hemoconcentr
abnorm
clot
profil
proteinuria
mortal
estim
puumala
dobrava
virus
princip
attack
kidney
clinic
ill
patient
enlarg
kidney
sonographi
minor
patient
manifest
ascit
dobrava
viru
infect
puumala
viru
infect
pleural
effus
dobrava
viru
infect
dobrava
virusinfect
patient
tend
ill
higher
serum
creatinin
urea
nitrogen
level
requir
dialysi
die
survey
pomurj
region
slovenia
found
case
hfr
occur
may
august
patient
outdoor
occup
median
age
year
patient
male
puumala
viru
caus
mani
case
dobrava
viru
versu
case
oligur
renal
failur
seen
puumala
virusinfect
patient
six
patient
puumala
viru
infect
one
two
patient
dobrava
viru
infect
hypotens
sign
shock
seven
patient
elev
cerebrospin
fluid
protein
patient
puumala
viru
patient
sinu
bradycardia
seoul
viru
produc
milder
diseas
febril
mild
hemorrhag
manifest
hepatomegali
mildli
elev
liver
enzym
puumala
viru
produc
mildest
infect
fever
petechia
onset
oliguria
day
diseas
ten
percent
patient
requir
dialysi
develop
revers
central
nervou
system
symptom
confus
dizzi
recent
outbreak
hfr
among
russian
militari
personnel
station
primorskii
region
report
greatest
number
case
within
week
first
case
case
year
old
mortal
studi
korean
war
veteran
contract
hfr
found
increas
longterm
mortal
question
increas
select
morbid
hypopituitar
atroph
pituitari
gland
empti
sella
mri
report
late
complic
hfr
aggress
support
therapi
ribavirin
shown
significantli
improv
surviv
kill
vaccin
avail
increas
human
safeti
data
anim
efficaci
data
insuffici
human
efficaci
safeti
data
support
food
drug
administr
licensur
formalin
inactiv
vaccin
hantaan
seoul
virus
use
asia
chines
monoval
vaccin
said
effect
chines
data
new
bival
vaccin
seroconvert
patient
advers
reaction
rate
hepat
b
viru
core
particl
aminotermin
amino
acid
nucleocapsid
dobrava
hantaan
puumala
virus
chimer
core
particl
found
highli
immunogen
balbc
mice
anoth
candid
vaccin
recombin
peromyscu
maniculatu
cytomegaloviru
vaccin
contain
sin
nombr
viru
glycoprotein
gi
fuse
enhanc
green
fluoresc
protein
gene
limit
human
exposur
rodent
excreta
essenti
prevent
diseas
two
studi
suggest
persontoperson
spread
hantaviru
type
caus
hp
unlik
hospit
set
one
studi
demonstr
possibl
differenti
diagnosi
includ
leptospirosi
typhu
pyelonephr
poststreptococc
glomerulonephr
acut
surgic
abdomen
hemorrhag
fever
although
hfr
transmiss
aerosol
technic
difficulti
stand
way
viru
mass
product
hanta
viru
pulmonari
syndrom
sin
nombr
viru
hp
incub
period
typic
week
rang
week
prodrom
stage
usual
day
rang
day
patient
abrupt
onset
symptom
fever
myalgia
malais
chill
anorexia
headach
patient
worsen
prostrat
signific
nausea
vomit
abdomin
pain
diarrhea
patient
present
mild
moder
gener
discomfort
cardiorespiratori
compromis
stage
patient
initi
short
breath
evid
pulmonari
edema
product
nonproduct
cough
tachypnea
fever
mild
hypotens
arteri
oxygen
desatur
chest
radiograph
may
initi
normal
progress
worsen
display
sign
pulmonari
edema
acut
respiratori
distress
syndrom
laboratori
abnorm
includ
thrombocytopenia
leukocytosi
atyp
lymphocyt
mildli
elev
aspart
transaminas
serum
prolong
partial
thromboplastin
time
increas
serum
lactat
dehydrogenas
lactic
acidosi
patient
develop
dic
bleed
patient
deterior
differ
rate
die
rapidli
wherea
other
deterior
desatur
slowli
death
occur
within
hour
admiss
one
third
patient
manag
success
patient
surviv
first
day
probabl
recov
independ
pulmonari
patholog
patient
found
low
cardiac
output
elev
system
vascular
resist
normal
low
pulmonari
wedg
pressur
patient
succumb
fatal
shock
lactic
acidosi
surviv
without
complic
therapi
often
discharg
week
renal
failur
requir
hemodialysi
accompani
acut
infect
ribavirin
appar
ineffect
intens
care
decreas
mortal
vigor
neutral
antibodi
respons
seem
predict
surviv
serolog
test
sin
nombr
viru
may
accomplish
elisa
western
blot
assay
ebola
viru
ebola
hemorrhag
fever
follow
rang
day
incub
period
patient
present
abrupt
onset
fever
sever
headach
myalgia
abdomin
pain
diarrhea
pharyng
herpeticlik
lesion
mouth
pharynx
sever
conjunctiv
inject
bleed
gum
lightskin
patient
often
promin
maculopapular
rash
evolv
petechia
ecchymosi
bleed
venepunctur
site
mucosa
hematemesi
bloodi
diarrhea
gener
mucos
hemorrhag
neurolog
complic
hemiplegia
psychosi
coma
seizur
common
patient
go
develop
shock
metabol
acidosi
diffus
coagulopathi
patient
succumb
day
mortal
rate
ebola
zair
ebola
sudan
mortal
rate
higher
infect
contamin
needl
initi
leucopenia
lymphopenia
replac
increas
white
blood
cell
count
appear
viralinfect
larg
abnorm
lymphocyt
dark
cytoplasm
virocyt
although
clinic
present
viral
infect
seem
sever
diseas
serosurvey
equatori
africa
found
seroposit
rate
filovirus
popul
suggest
diseas
mayb
widespread
common
infect
mild
asymptomat
differenti
diagnosi
lassa
fever
diagnosi
made
first
day
ill
isol
viru
vero
cell
biosafeti
level
laboratori
antigen
may
detect
rtpcr
antigencaptur
elisa
igm
igg
antibodi
may
detect
elisa
test
strict
isol
safe
burial
practic
activ
surveil
system
describ
present
vaccin
therapi
avail
marburg
ebola
viru
hemorrhag
fever
filoviru
matrix
protein
drive
spontan
product
releas
viruslik
particl
resembl
infecti
virion
addit
filoviru
protein
filoviru
glycoprotein
increas
viruslik
particl
product
particl
express
multipl
filoviru
antigen
inject
rodent
ebola
marburg
viruslik
particl
contain
glycoprotein
protect
lethal
challeng
ebola
marburg
virus
cytotox
lymphocyt
essenti
surviv
ebola
viru
infect
mice
vaccin
venezuelan
equin
enceph
viru
replicon
encod
ebola
viru
nucleoprotein
surviv
normal
lethal
ebola
viru
infect
polyclon
antiserum
ebola
viru
nucleoprotein
protect
wherea
transfer
cytotox
lymphocyt
specif
ebola
viru
nucleoprotein
protect
ebola
viru
infect
vaccin
ebola
viru
particularli
difficult
develop
diseas
observ
primat
differ
diseas
rodent
work
unsuccess
vaccin
candid
attenu
venezuelan
equin
enceph
viru
express
ebola
glycoprotein
nucleoprotein
recombin
vaccinia
viru
express
ebola
glycoprotein
liposom
contain
lipid
inactiv
ebola
viru
concentr
inactiv
wholevirion
prepar
demonstr
protect
ebola
mice
guinea
pig
fail
nonhuman
primat
vaccin
ebola
marburg
virus
base
recombin
vesicular
stomat
viru
shown
protect
macaqu
lethal
dose
correspond
filoviru
predict
epidem
spread
ebola
attempt
monitor
spread
diseas
nonhuman
primat
ebola
outbreak
forest
zone
gabon
republ
congo
congo
result
handl
wild
anim
carcass
die
infect
monitor
system
collect
carcass
analysi
found
gorilla
chimpanze
duiker
seroposit
ebola
viru
five
human
ebola
outbreak
preced
anim
zootic
surveil
method
abl
alert
health
depart
two
outbreak
week
advanc
clinic
present
marburg
viru
infect
similar
ebola
viru
incub
period
day
sudden
onset
fever
chill
headach
myalgia
day
ill
may
progress
sever
hemorrhag
fever
fifth
day
ill
patient
develop
maculopapular
rash
follow
nausea
vomit
chest
pain
sore
throat
abdomin
pain
diarrhea
patient
becom
wors
jaundic
pancreat
weight
loss
delirium
shock
liver
failur
massiv
bleed
multiorgan
failur
develop
although
mortal
record
closer
viru
may
isol
survivor
semen
long
month
recoveri
uveiti
viral
isol
anterior
chamber
report
diagnosi
made
isol
viru
biosafeti
level
laboratori
antigen
may
detect
pcr
antigencaptur
elisa
igm
igg
antibodi
may
persist
long
period
effect
public
health
respons
seen
outbreak
angola
involv
accur
diagnosi
isol
patient
contact
proper
infect
control
procedur
health
care
facil
strict
isol
precaut
patient
absolut
necessari
vaccin
specif
antivir
therapi
present
avail
dengu
dengu
hemorrhag
fever
common
vhf
estim
million
case
per
year
worldwid
diseas
found
everi
tropic
countri
princip
spread
aegypti
four
serotyp
produc
three
clinic
syndrom
nonspecif
febril
ill
dengu
fever
fever
arthralgia
rash
dengu
hemorrhag
fever
classic
dengu
incub
period
dengu
day
patient
develop
break
bone
fever
sudden
onset
high
fever
sever
muscl
pain
headach
prostrat
facial
flush
retroorbit
pain
conjunctiv
inject
half
patient
earli
transient
erythemat
rash
patient
remain
febril
anorex
restless
day
display
mild
hemorrhag
sign
posit
tourniquet
test
epistaxi
petechia
purpura
platelet
count
usual
mm
may
drop
low
level
white
blood
cell
count
fever
rapidli
resolv
morbilliform
scarlatiniform
rash
appear
first
extrem
petechia
leg
along
gener
lymphadenopathi
liver
enzym
abnorm
usual
hepatomegali
second
febril
phase
last
day
follow
desquam
rash
convalesc
long
patient
remain
debilit
depress
period
dengu
hemorrhag
fever
dengu
hemorrhag
fever
begin
day
classic
ill
time
patient
goe
shock
exhibit
restless
diaphoresi
hypotens
hemorrhag
manifest
posit
tourniquet
test
petechia
purpura
spontan
bleed
gum
gastrointestin
tract
liver
becom
enlarg
tender
patient
develop
hypoproteinemia
hyponatremia
mild
elev
liver
enzym
thrombocytopenia
sometim
develop
increas
capillari
permeabl
hemoconcentr
hematocrit
increas
dic
leucopenia
patient
develop
hypotens
dengu
shock
syndrom
respiratori
failur
ensu
alveolar
hemorrhag
fluid
accumul
renal
failur
secondari
hypotens
immun
complex
deposit
rare
encephalopathi
follow
mortal
dengu
hemorrhag
fever
may
reduc
adequ
fluid
resuscit
viru
may
detect
earli
diseas
growth
cell
cultur
rna
detect
pcr
serolog
test
also
avail
hemagglutin
inhibit
test
enzym
immunoassay
immunofluoresc
assay
acut
convalesc
serum
sampl
specif
antivir
therapi
aggress
support
therapi
necessari
candid
vaccin
chemotherapeut
agent
discuss
see
yellow
fever
next
strict
isol
except
exclus
mosquito
necessari
ampligen
polyi
mismatch
doublestrand
rna
induc
interferon
product
investig
therapi
chronic
fatigu
syndrom
hiv
infect
epsteinbarr
virusposit
hodgkin
lymphoma
sever
acut
respiratori
syndrom
hepat
c
renal
cell
carcinoma
invas
metastat
malign
melanoma
immun
dysfunct
syndrom
flavivirus
west
nile
viru
equin
enceph
viru
dengu
fever
viru
japanes
enceph
viru
hemispherx
biopharma
oral
ampligenlik
compound
avail
could
possibl
great
valu
masscasualti
set
liveattenu
vaccin
avail
increas
human
safeti
data
anim
efficaci
data
insuffici
human
efficaci
safeti
data
support
food
drug
administr
licensur
author
consid
dengu
bioterror
risk
primari
dengu
rare
caus
hemorrhag
fever
seem
transmiss
small
particl
inhal
other
howev
think
otherwis
exampl
dr
kamal
datta
director
nation
institut
communic
diseas
india
refer
outbreak
dengu
delhi
case
death
suspici
yellow
fever
found
tropic
africa
south
central
america
nineteenth
earli
twentieth
centuri
also
endem
temper
area
far
north
philadelphia
viru
maintain
haemagogu
sabeth
mosquito
forest
aegypti
usual
respons
outbreak
popul
center
africa
monkeymosquitomonkey
cycl
involv
aed
speci
brazil
amblyomma
variegatum
tick
transmit
viru
transstadi
pass
viru
uninfect
monkey
incub
period
day
endem
area
mani
unappar
infect
signific
immun
symptomat
infect
mild
patient
recov
within
hour
less
minor
patient
sever
headach
myalgia
low
back
pain
proteinuria
patient
exhibit
rel
bradycardia
degre
fever
faget
sign
patient
sever
ill
abrupt
onset
high
fever
sever
headach
nausea
vomit
abdomin
back
loin
limb
pain
patient
becom
dehydr
jaundic
develop
bleed
nose
gum
period
infect
viremia
last
day
patient
may
enter
recoveri
phase
temporarili
improv
next
hour
rapidli
deterior
jaundic
deepen
patient
develop
epigastr
pain
vomit
gastrointestin
bleed
patient
becom
hypotens
develop
heart
failur
prolong
pr
qt
interv
ekg
patient
may
recov
day
week
death
may
occur
seventh
tenth
day
complic
includ
parot
pneumonia
increas
proteinuria
bleed
tachycardia
oliguria
renal
insuffici
hypotens
bad
prognost
sign
mortal
viru
may
isol
blood
first
day
method
diagnosi
antigencaptur
enzym
immunoassay
rtpcr
liver
biopsi
specimen
immunofluoresc
assay
probe
hybrid
rtpcr
licens
liveattenu
vaccin
avail
kyasanur
forest
diseas
tickborn
haemaphysali
tick
flaviviru
southwestern
india
incub
period
produc
febril
hemorrhag
diseas
vaccin
avail
infect
control
method
includ
treatment
cow
tick
infest
use
insect
repel
mortal
asymptomat
infect
probabl
occur
serolog
studi
sampl
six
locat
andaman
nocobar
island
india
found
antibodi
preval
potenti
use
bioterrorist
weapon
viru
requir
biosafeti
level
laboratori
isol
dermacentor
tick
principl
reservoir
infect
found
mani
small
mammal
siberia
includ
muskrat
human
infect
acquir
either
handl
dead
carcass
tick
bite
infect
muskrat
hunter
often
asymptomat
incub
period
symptomat
diseas
develop
papulovesicular
lesion
soft
palat
mucos
gastrointestin
bleed
mortal
symptomat
case
balbc
mous
model
use
omsk
hemorrhag
fever
neurotrop
flaviviru
powassan
viru
patholog
differ
cerebellar
involv
powassan
viru
infect
differ
splenic
patholog
demonstr
omsk
viral
antigen
seen
spleen
brain
endotheli
cell
liver
absent
kidney
powassan
viru
detect
brain
absent
spleen
kidney
distribut
viral
particl
brain
differ
potenti
use
bioterrorist
weapon
viru
requir
biosafeti
level
laboratori
isol
four
pilgrim
hajj
holi
citi
mecca
saudi
arabia
identifi
februari
year
typic
vhf
new
flaviviru
close
rel
tickborn
kyasanur
forest
diseas
viru
viru
isol
six
patient
denguelik
hemorrhag
fever
alkhumra
district
south
jeddah
saudi
arabia
investig
found
two
addit
case
butcher
organ
recov
wound
sourc
infect
identifi
origin
case
includ
contamin
wound
butcher
six
tick
bite
student
engin
two
consumpt
raw
camel
milk
soldier
driver
poultri
worker
three
investig
identifi
patient
laboratori
confirm
present
acut
febril
flulik
ill
hepat
half
display
hemorrhag
find
enceph
conclud
diseas
transmit
mosquito
bite
direct
contact
infect
sheep
goat
rodent
viru
maintain
natur
investig
case
identifi
four
die
overal
mortal
outbreak
potenti
use
bioterrorist
weapon
viru
requir
biosafeti
level
laboratori
isol
specif
pharmacolog
therapi
ribavirin
vhf
recommend
lassa
fever
arenaviru
hemorrhag
fever
rift
valley
fever
cchf
hfr
relat
virus
specif
antivir
therapi
avail
flaviviru
filoviru
hemorrhag
fever
lack
approv
vaccin
prove
prophylaxi
surviv
mani
sever
ill
patient
inpati
intens
care
make
group
virus
potenti
bioterror
agent
intent
overwhelm
societi
resourc
mobil
immedi
need
vaccin
develop
specif
prophylact
therapeut
intervent
strengthen
public
health
respons
includ
effici
system
monitor
contact
popul
risk
invigor
hospit
infect
control
practic
effect
region
nation
triag
system
expans
inpati
isol
facil
accommod
intens
level
care
region
inpati
intens
care
facil
maxim
care
may
deliv
sickest
victim
develop
effect
accept
outpati
therapeut
care
uniqu
suggest
develop
immun
respons
modifi
stimul
immun
system
antivir
antineoplast
activ
coley
pharmaceut
group
pharmaceut
hybridon
sciclon
hemispherx
biopharma
corixa
corpor
afg
biosolut
product
variou
stage
develop
hybridon
secondgener
immunomodulatori
oligonucleotid
may
potenti
use
prophylaxi
therapeut
variola
dengu
ebola
addit
pathogen
tolllik
receptor
immun
cell
recogn
pathogen
macromolecul
wide
specif
pharmaceut
aldara
imiquimod
shown
activ
human
papillomaviru
molluscum
contagiosum
leishmaniasi
approv
treatment
actin
keratos
basal
cell
carcinoma
genit
wart
drug
stimul
tolllik
tolllik
activ
mous
primat
model
herp
simplex
cytomegaloviru
influenza
banziviru
rift
valley
fever
west
nile
viru
coley
pharmaceut
group
gpg
tolllik
agonist
best
defens
prevent
worldwid
inventori
exist
viral
stock
must
accur
record
secur
aggress
intern
profil
track
individu
acquir
seek
acquir
special
viral
laboratori
equip
viral
cultur
viral
host
vector
visit
viral
habitat
contact
natur
victim
need
undertaken
program
deter
determin
resourc
elabor
sponsor
malefactor
deni
resourc
determin
wellfinanc
enemi
protect
foreign
govern
intern
boundari
difficult
imposs
intellig
agenc
clandestin
target
state
stateless
organ
abl
address
threat
remaind
valuabl
frequent
updat
resourc
tabul
etiolog
agent
characterist
resourc
list
clinic
pathway
may
found
infecti
diseas
societi
america
websit
http
www
idsocietyorg
resourc
bioterror
